Snowflake AI Partnerships Raise Hope, But NRR Inflection Still Needed

What happened

Snowflake's new partnerships with AWS and Anthropic signal growing traction for its AI platform, with record AI product adoption and strong customer growth. However, the latest DeepValue report maintains a WAIT rating, highlighting that key retention metric NRR remains at 125%, below the 130% threshold needed to confirm AI-driven consumption expansion. The $7.88B RPO backlog and 29% product revenue growth are positive, but the report warns that discounting on large deals and open-format competition could compress margins and delay revenue conversion. The stock at $183 prices in an AI acceleration that has not yet materialized in net revenue retention, making the next two quarters critical for evidence of sustainable expansion. Investors should await either an NRR uptick or a pullback toward the $160 attractive entry before committing new capital.

Implication

In the near term, the AWS and Anthropic deals provide narrative support but do not change the fundamental thesis: SNOW must prove that AI workloads convert into sustained consumption growth, visible in NRR above 130%. The report's base case of $190 implies limited upside from current levels, while the bear case of $150 highlights risks from consumption optimization and margin pressure. Long-term investors should monitor quarterly NRR and operating margin trends; a sustained NRR at or above 130% would justify adding, while a slip below 120% would signal thesis breakage. The $160 entry point offers a better risk/reward, compensating for stock-based compensation dilution and GAAP losses. Until then, the stock remains a show-me story despite positive partnership headlines.

Thesis delta

The partnerships add credibility to Snowflake's AI adoption story but do not shift the core thesis: the stock still needs to demonstrate that AI workloads drive a step-change in net revenue retention above the mid-120s band. The investment case remains dependent on converting $7.88B in RPO into revenue without persistent discounting or margin erosion. No change to the WAIT rating; the balance of evidence still favors waiting for either NRR inflection or a lower entry price.